Clinical trials
Completed Lung Diseases, Interstitial trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2014 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 5 |
| Peking Union Medical College Hospital | 2 |
| Bristol-Myers Squibb | 1 |
| Changchun GeneScience Pharmaceutical Co., Ltd. | 1 |
| Children's Hospital of Fudan University | 1 |
| China-Japan Friendship Hospital | 1 |
| InSilico Medicine Hong Kong Limited | 1 |
| Shandong Cancer Hospital and Institute | 1 |
| Shanghai East Hospital | 1 |
| The First Affiliated Hospital of Guangzhou Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Diseases, Interstitial | 16 |
| Idiopathic Pulmonary Fibrosis | 2 |
| Pulmonary Fibrosis | 2 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Fibrosis | 1 |
| Idiopathic Interstitial Pneumonias | 1 |
| Lung Diseases | 1 |
| Pathologic Processes | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Respiratory Tract Diseases | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.